Aa
Recurrent ovarian cancer treatment
Hello,
My dx was stage 3c in 6/2008. I was a participant in the GOG trial using standard chemo plus either Avastin or a placebo however my cancer recurred almost immediately upon completion of the 6 treatments of Carbo/Taxol. My oncologist is now recommending Topotecan for my next round, 3 weeks on 1 week off. My question is why is one drug suggested over another ie. why not Doxil or Gemzar? Also, are there any statistics showing the rate of success of Topo for second line therapy?
Thanks,
Sharon
My dx was stage 3c in 6/2008. I was a participant in the GOG trial using standard chemo plus either Avastin or a placebo however my cancer recurred almost immediately upon completion of the 6 treatments of Carbo/Taxol. My oncologist is now recommending Topotecan for my next round, 3 weeks on 1 week off. My question is why is one drug suggested over another ie. why not Doxil or Gemzar? Also, are there any statistics showing the rate of success of Topo for second line therapy?
Thanks,
Sharon
MEDICAL PROFESSIONAL
Hi Sharon, I wish you good luck!
I had a total hysterectomy with optimal debulking. Highest CA 125 was 2900, it went to 28 after 6 rounds of Carbo/Taxol. There was a 7mm spot leftover which when grew to 9mm in 2 months. Biopsy done on 3/6/09 confirmed malignancy.
Thank you for your prompt reply to my question. Will give the Topotecan a try and hope for stability.
Sharon
Thank you for your prompt reply to my question. Will give the Topotecan a try and hope for stability.
Sharon
MEDICAL PROFESSIONAL
Hi,
I assume that you got the chemo for the commoner epithelial type of ovarian cancer. What surgery was performed? What were the Ca 125 levels before and after chemotherapy? Did the cancer disappear completely before re-appearing?
Your cancer is platinum resistant, as it came back shortly after completing platinum based treatment.
According to the NCCN (National Comprehensive Cancer Network) 2009 guidelines, acceptable chemotherapy drugs in relapsed (platinum resistant) ovarian cancer include liopsomal doxorubicin, docetaxel, gemcitabine, etoposide, paclitaxel (weekly), pemetrexed, and topotecan.
There is no overwhelming data to support the selection of one drug over the others, and doctor and patient preference plays a large part in deciding which agent to choose. In phase III clinical trials, topotecan proved to be equivalent in efficacy to both paclitaxel and liposomal doxorubicin as second-line therapy in patients with relapsed ovarian cancer.
Alternatively, you may decide to enrole in another clinical trial.
All the best, and God Bless!
I assume that you got the chemo for the commoner epithelial type of ovarian cancer. What surgery was performed? What were the Ca 125 levels before and after chemotherapy? Did the cancer disappear completely before re-appearing?
Your cancer is platinum resistant, as it came back shortly after completing platinum based treatment.
According to the NCCN (National Comprehensive Cancer Network) 2009 guidelines, acceptable chemotherapy drugs in relapsed (platinum resistant) ovarian cancer include liopsomal doxorubicin, docetaxel, gemcitabine, etoposide, paclitaxel (weekly), pemetrexed, and topotecan.
There is no overwhelming data to support the selection of one drug over the others, and doctor and patient preference plays a large part in deciding which agent to choose. In phase III clinical trials, topotecan proved to be equivalent in efficacy to both paclitaxel and liposomal doxorubicin as second-line therapy in patients with relapsed ovarian cancer.
Alternatively, you may decide to enrole in another clinical trial.
All the best, and God Bless!
You are reading content posted in the Chemotherapy Forum
Here are 15 ways to help prevent lung cancer.
New cervical cancer screening guidelines change when and how women should be tested for the disease.
They got it all wrong: Why the PSA test is imperative for saving lives from prostate cancer
Everything you wanted to know about colonoscopy but were afraid to ask
A quick primer on the different ways breast cancer can be treated.
Get the facts about this disease that affects more than 240,000 men each year.
